Pembrolizumab injection

Pembrolizumab injection FDA granted accelerated approval to pembrolizumab (KEYTRUDA Injection, Merck Sharp and Dohme Corporation) for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors express programmed death ligand 1 (PD-L1) as determined by an FDA-approved test, with disease progression on or after platinum-containing chemotherapy. Patients with EGFR or ALK genomicContinue reading “Pembrolizumab injection”